Fluorine-18 NY 104 - Norroy Bioscience
Alternative Names: 18F NY104; Fluorine-18 NY-104Latest Information Update: 05 Sep 2024
At a glance
- Originator Norroy Bioscience
- Class Imaging agents; Radioisotopes; Radiopharmaceutical diagnostics; Small molecules
- Mechanism of Action Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Renal cancer
Most Recent Events
- 05 Sep 2024 Norroy Bioscience Pipeline, September 2024: No updates; profile already created
- 02 Aug 2024 Preclinical trials in Renal cancer (Diagnosis) in China (unspecified route) (Norroy Bioscience pipeline; July 2024)
- 02 Aug 2024 Norroy Bioscience intends to file a regulatory application for approval of Fluorine-18 NY 104 for Renal cell carcinoma (Diagnosis) in the second half of 2025 (Norroy Bioscience pipeline, July 2024)